Vaccine development against Leishmania donovani
Visceral leishmaniasis (VL) caused by Leishmania donovani and Leishmania infantum/ chagasi represents the second most challenging infectious disease worldwide, affecting nearly 500,000 people and 60,000 deaths annually. Zoonotic VL (ZVL) caused by L. infantum is re-emergent canid zoonoses which rep...
Main Authors: | Amrita eDas, NAHID eALI |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2012.00099/full |
Similar Items
-
Low prevalence of <it>Leishmania donovani</it> infection among the blood donors in kala-azar endemic areas of Bangladesh
by: Huda M Mamun, et al.
Published: (2013-02-01) -
Kala-azar in a Brazilian child
by: Michael K. Hole, et al.
Published: (2011-04-01) -
Kala-azar Epidemiology and Control, Southern Sudan
by: Jan H. Kolaczinski, et al.
Published: (2008-04-01) -
Kala-azar Control, Uganda
by: Jan H. Kolaczinski, et al.
Published: (2007-03-01) -
The FML (Fucose Mannose Ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar
by: Claris B. Palatnik de Sousa, et al.
Published: (1996-04-01)